Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

---------

MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 (dirucotide) is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The apparent mechanism of action of MBP8298 (dirucotide) is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 (dirucotide) for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 year
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... PDS, a leader in providing smart and effi...nces Pajama Pathology®, evolutionizing work-fr...o;gold standard’ software used by 8 of the T...n a ‘cost per slide’ basis. , ...ber 30, 2009 -- PDS has announced another evolutio...
(Date:11/30/2009)...TON and COPENHAGEN, Nov. 30 Exiqon...y that the Harvard Medical School ICCB-Longwood Sc... MicroRNA Screening Center of Excellence. ICCB-L ...and associated hospitals and institutions, for hig...libraries. ,, MicroRNAs are a novel class of sm...
(Date:11/30/2009)..., LONDON, November 30 ApaTec... named Europe,s fastest growing,Biotech/Pharmaceut...eloitte,2009 Technology Fast 500 for EMEA (Europe,...anking is based on a companies, five-year revenue ...,318% over this period. This,achievement places Ap...
(Date:11/29/2009)...s available in German . , The concept of co...ysics. The most famous example is that of quarks w...ow Prof. Bella Lake from Helmholtz-Zentrum Berlin ...report for the first time an experimental realizat... in a condensed matter system. , The concept of ...
Breaking Biology Technology:Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4Spinons -- confined like quarks 2
...ED FOR TUESDAY, OCTOBER 28, SAN DIEGO, Oct. 22 N...ced today that the Company will report its third,q...ket closes on Tuesday,October 28, 2008. Neurocrine...iscuss its financial results and provide a Company...0 p.m. Eastern Time (2:00 p.m. Pacific,Time)., Pa...
...Inc.,(Nasdaq: TELK ) announced that its 2008 thir... on Wednesday, November 5, 2008 at 4:30 p.m. Easte...ease earlier that day of the,company,s financial r...008., The conference call will be accessible via ...lephone at 800-398-9367 or 612-332-7517. An,archiv...
...r Systems, Inc., a,medical device company developi... announced today that it has signed an agreement w...ercialize StemCor,s proprietary System,for the har...com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO ), S...spira will manage,the clinical trial program, lead...
Other Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 3
(Date:11/26/2009)...ers, red deer have been caught in the hunters, sig... more than decorative. They are lethal weapons tha... from The University of York, UK, has been intrigu...alf a century and has become fascinated by the mec...ng collaboration with Tomas Landete-Castillejos at...
(Date:11/26/2009)...phylococcus Aureus ) and other drug-resistant bact...asma prototype devices have been developed to offe...ktails. , Two prototype devices have been develo...n (e.g. hands and feet) in hospitals and public sp...another to shoot bacteria-killing agents into infe...
(Date:11/25/2009)... Cell Death Research Laboratory in the University ... the prestigious Johnson & Johnson Focused Funding...in cell damage in Parkinson,s disease. The award, ...t of innovation and excellence in science, was ann...his month at an event at the Hyatt Regency Hotel i...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 1New Media Led Effort Responds to AIDS Crisis in Black America 50086 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 3New Media Led Effort Responds to AIDS Crisis in Black America 50086 4New Media Led Effort Responds to AIDS Crisis in Black America 50086 5New Media Led Effort Responds to AIDS Crisis in Black America 50086 6Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2U M study finds voice box can be preserved even with the largest cancers 50080 1U M study finds voice box can be preserved even with the largest cancers 50080 2
...gy infrastructure for researching and developing n...e industry hundreds of millions of dollars annuall... the National Institute of Standards and Technolog...T, the studys authors found that over the last two...ted from small-molecule chemicals to large-molecul...
...archers contributed to a national effort to sequen...hat will help advance research in a broad range of... to understanding a variety of human diseases. , ...ectionately as Chlamy, has long fascinated scienti...s that retains characteristics of both. Like green...
...greatly improves the ability to separate global wa...e gas is prepared for use, according to engineers ...yzed the new plastics performance. , Like a spong...astic permits carbon dioxide or other small molecu...t, while impeding natural gas (methane) movement t...
Other Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2'Chlamy' genome holds clues for renewable energy, the environment and human health 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
Anti-JNK1 / SAPK Antibody, Unconjugated from Cell Sciences
Acrylamide, Molecular Biology Grade from Research Organics, Inc.
UltraClean Low Melt Agarose from Mo Bio Laboratories, Inc.
Mouse Anti-Human QPRT Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Biology Products: